Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyell Immunopharma, Inc. (Nasdaq: LYEL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Lyell is a late-stage clinical company developing next-generation CAR T-cell therapies for cancer, and its filings give structured insight into how it reports clinical, financial, and corporate developments.
Among the key documents are Current Reports on Form 8‑K, where Lyell furnishes press releases on quarterly financial results and business highlights, including updates on pivotal trials of rondecabtagene autoleucel (ronde‑cel/LYL314) in relapsed and/or refractory large B-cell lymphoma and progress in its broader CAR T-cell pipeline. Other 8‑K filings describe material agreements, such as the Exclusive License Agreement granting Lyell rights to the GCC‑targeted CAR T-cell product candidate LYL273, and a Securities Purchase Agreement for a private placement of common stock and potential pre‑funded warrants to fund pivotal-stage trials.
Filings also detail unregistered sales of equity securities related to private placements, milestone share issuances following an acquisition, and equity consideration under licensing arrangements. Additional 8‑K items cover changes in key officers, including appointments and resignations in financial leadership roles, providing context on corporate governance and management structure.
On Stock Titan, these filings are complemented by AI-powered tools that can help summarize lengthy documents, highlight items such as financing terms, licensing economics, and clinical milestone triggers, and surface relevant sections across multiple reports. Users interested in LYEL can review Forms 8‑K and other periodic reports as they become available to track how Lyell discloses clinical progress, capital structure changes, and significant agreements connected to its CAR T-cell programs.
Lyell Immunopharma’s Chief Scientific Officer, Gary K. Lee, reported an open-market sale of 1,671 shares of common stock on February 11, 2026. The shares were automatically sold to cover tax withholding from performance-based vested restricted stock units.
The weighted average sale price was $23.39 per share, within a disclosed range of $23.3939 to $24.6305. After this tax-related sale, Lee directly beneficially owns 16,938 shares of Lyell Immunopharma common stock.
Lyell Immunopharma Chief Operating Officer Stephen J. Hill reported several equity transactions. He received 4,000 shares of common stock on February 9, 2026 from performance-based restricted stock units that vested after meeting certified performance criteria. On February 10, 2026 he was granted an option for 65,000 shares of common stock at an exercise price of $23.71 per share, with vesting beginning six months after February 9, 2026 and continuing monthly until fully vested, contingent on continued service. Also on February 10, he sold 109 shares at $23.12 per share to cover tax withholding from vested restricted stock units, leaving him with 19,031 common shares held directly.
Lyell Immunopharma’s Chief Scientific Officer Gary K. Lee reported several equity transactions. On February 9, 2026, he acquired 4,000 shares of common stock at $0 from performance-based restricted stock units, bringing his direct holdings to 18,756 shares.
On February 10, 2026, Lee was granted an option for 50,000 shares of common stock at an exercise price of $23.71, vesting over time through February 9, 2036. That same day, 147 shares were sold at $23.12 to cover tax withholding from vested restricted stock units, leaving him with 18,609 common shares held directly.
Lyell Immunopharma President and CEO Lynn Seely reported several equity compensation transactions. On February 9, 2026, Seely acquired 20,000 shares of common stock at $0, issued upon achievement of performance-based restricted stock unit criteria, bringing direct holdings to 82,159 shares.
On February 10, 2026, Seely sold 438 common shares at $23.12 per share, described as an automatic sale to cover tax withholding from vested restricted stock units, leaving 81,721 shares held directly. Also on February 10, Seely received a new option grant for 155,000 shares at an exercise price of $23.71 per share, vesting 12.5% six months after February 9, 2026 and then monthly in equal installments until fully vested, contingent on continued service.
Lyell Immunopharma General Counsel Mark A. Meltz received a grant of options to purchase 50,000 shares of common stock on February 10, 2026. The options have an exercise price of $23.71 per share and are held directly by him.
According to the vesting schedule, 12.5% of the shares subject to the option become vested and exercisable six months after February 9, 2026. The remaining shares vest in equal monthly installments of 1/48 of the total, so the option becomes fully vested over four years, contingent on his continued service.
Lyell Immunopharma VP, Corporate Controller Veronica Sanchez Bulis reported an equity grant and a small share sale. On February 10, 2026, she received 8,750 restricted stock units under Lyell’s 2021 Equity Incentive Plan at $0 per share equivalent, increasing her holdings to 15,891 common shares.
The RSUs vest over time: 12.5% on August 9, 2026, then 1/16 of the total vests quarterly, as long as she continues providing service. The filing also shows an open-market sale of 254 common shares at $23.12 per share, executed automatically to cover tax withholding from vested RSUs, leaving her with 15,637 directly owned shares.
Lyell Immunopharma Chief Medical Officer David Shook received a grant of stock options. On February 10, 2026, he was awarded an option to buy 50,000 shares of Lyell Immunopharma common stock at an exercise price of $23.71 per share.
The option vests over time: 12.5% of the shares become exercisable six months after February 9, 2026, and the remaining shares vest in equal monthly installments until fully vested, as long as he continues providing service. Following this grant, he also directly held 21,900 shares of common stock.
Lyell Immunopharma VP Veronica Sanchez Bulis reported two sales of company stock. On 12/24/2025 she sold 1,136 shares of common stock at a weighted average price of $38.67 per share, in a series of trades where individual prices ranged from $38.6643 to $38.6751 per share. On 12/30/2025 she sold an additional 936 shares at $32.32 per share. After these transactions, she held 7,141 shares of Lyell Immunopharma common stock directly.
Lyell Immunopharma, Inc. is registering up to 1,900,000 shares of common stock for resale by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings). These shares were issued to ICT Holdings on November 6, 2025 as part of the upfront consideration under an exclusive license agreement covering certain cell therapy product candidates and products worldwide, excluding mainland China, Taiwan, Macau and Hong Kong.
Under the License Agreement, Lyell paid ICT Holdings $40 million in cash and issued 1.9 million shares, and may owe up to $30 million in clinical milestones, up to $115 million in late-stage regulatory milestones, up to $675 million in commercial sales milestones, up to 1.85 million additional shares, and tiered royalties up to 10% in the United States and low to mid-single digits elsewhere in the territory.
Lyell will not sell any shares or receive any proceeds from ICT Holdings’ sales. Lyell’s stock trades on Nasdaq under “LYEL,” and a 1-for-20 reverse stock split reduced outstanding shares to approximately 14,808,006 on May 30, 2025.
Lyell Immunopharma, Inc. has filed a resale registration for up to 1,900,000 shares of common stock held by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings). These shares were issued on November 6, 2025 as part of the consideration under an Exclusive License Agreement granting Lyell worldwide rights, outside mainland China, Taiwan, Macau and Hong Kong, to research, develop, manufacture and commercialize certain cell therapy product candidates and products.
Lyell paid ICT Holdings $40 million in cash and issued 1.9 million shares, and may owe up to $30 million in clinical milestones, up to $115 million in late-stage regulatory milestones, up to $675 million in commercial sales milestones, and up to an additional 1.85 million shares upon specified milestones, plus tiered royalties. All 1,900,000 registered shares may be sold from time to time by ICT Holdings, and Lyell will not receive any proceeds from these sales.